Vanguard Capital Management
TNXP icon

Vanguard Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Vanguard Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.83M Buy
691,895
+173,245
+33% +$2.24M ﹤0.01% 2893
2026
Q1 		$7.13M Buy
+518,650
New +$7.98M ﹤0.01% 2908

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
JHC
Jones Hill Capital New York $470M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management's TNXP Position: Q2 2026 in Review

Vanguard Capital Management increased its Tonix Pharmaceuticals (TNXP) stake by 33% in Q2 2026, buying an estimated $2.24M and bringing the position to 691,895 shares worth $8.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2893.

Vanguard Capital Management first reported a position in TNXP in Q1 2026 and has held it in 2 quarters since. 101 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • Vanguard Capital Management held 691,895 shares of Tonix Pharmaceuticals worth $8.83M as of Q2 2026.
  • Vanguard Capital Management bought 173,245 Tonix Pharmaceuticals shares in Q2 2026, an estimated $2.24M.
  • Tonix Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2893 holding.
  • Vanguard Capital Management first reported a position in Tonix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 101 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.